trial

Personalized Prospective Study Evaluation of the Efficacy and Safety of Noninvasive Neuromodulation of TMS in Subjects With Catatonia

NCTId NCT06176456
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Unknown
Enrollment 60 (estimated)
Sponsored by Moscow Psychiatric Hospital No. 1 Named after N.A. Alexeev
Primary completion 2024-05-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Unknown
Enrollment
60 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Sequential
Masking
Triple
Start
2023-11-01
Primary completion
2024-05-01
Eligibility
ALL · 18 Years · 35 Years

Interventions & indications

Drugs
rTMS

Sponsors

Moscow Psychiatric Hospital No. 1 Named after N.A. AlexeevLead Sponsor

Sites

1 total
Moscow, Russia

Facts & assertions

4 sourced
Enrollment
60
Phase
NA
Primary Completion Date
2024-05-01
Status
UNKNOWN
relationships
The graph out of here
drug
rTMS
drug
lead_sponsor
Moscow Psychiatric Hospital No. 1 Named after N.A. Alexeev
company
indication
Schizo Affective Disorder
indication
Bipolar Disorder
indication
Catatonia
indication